Conatus Pharma (CNAT) Says Emricasan Abstracts Accepted for AASLD Meeting
- Consumer staples stocks help Wall St. pare some losses
- BAT Reaches Deal to Acquire Reynolds American (RAI) for $49 Billion
- Verizon Communications (VZ) May Acquire Big Cable Company - NYP (CHTR) (CMCSA)
- Citron Research Negative on Lannett (LCI); Sees Shares at 'Zero' Over Long Term
- Einhorn's Greenlight Mentions Caterpillar (CAT) Short in Q4 Letter; Doesn't See Disney (DIS) Buying Netflix (NFLX)
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today that abstracts for four posters – two addressing clinical results and two addressing preclinical results with the company’s pan-caspase inhibitor, emricasan – have been accepted for presentation at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston November 11-15, 2016.
Accepted abstracts were published today on the AASLD website at www.aasld.org/ for posters entitled:
- “Emricasan (IDN-6556) Orally for 6 Months in Patients with Cirrhosis and Elevated MELD Score Improves Liver Function,” (poster #2095);
- “Emricasan (IDN-6556) Orally for 6 Months in Patients with Non-alcoholic Steatohepatitis (NASH) Cirrhosis Decreases the Progression of MELD score and Improves Liver Function,” (poster #2099);
- “Circulating microparticles carry apoptosis markers CK-18 and caspase-3/7 which are reduced by treatment with Emricasan in subjects with chronic liver diseases,” (poster #2098); and
- “The pan caspase inhibitor Emricasan improves the hepatic microcirculatory dysfunction of CCl4-cirrhotic rats leading to portal hypertension amelioration and cirrhosis regression,” (poster #2097).
- Both poster #2095 and poster #2097 were accepted as “Presidential Posters of Distinction,” indicating review scores that place them within the top 10 percent of all posters submitted.
“We continue accumulating clinical evidence of emricasan’s disease-modifying potential as we advance toward an initial registration in patients with liver cirrhosis caused by nonalcoholic steatohepatitis (NASH),” said Conatus co-founder, President and Chief Executive Officer Steven J. Mento, Ph.D., “while simultaneously confirming emricasan’s multiple mechanistic effects on liver structure and function through preclinical studies. We are pleased with the opportunity to highlight the latest developments in both areas at the upcoming AASLD meeting, providing a deeper scientific understanding of the medical benefits observed in our clinical trials.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Facebook's virtual-reality tech was not stolen, Zuckerberg testifies
- Corbus Pharma (CRBP) Receives UE Orphan Designation for JBT-101 for Treatment of Systemic Sclerosis
- Forward Pharma (FWP) Confirms Settlement and License Agreement with Biogen (BIIB)
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!